AgomAb Therapeutics Management
Management criteria checks 1/4
AgomAb Therapeutics' CEO is Tim Knotnerus, appointed in Feb 2019, has a tenure of 7.25 years. directly owns 0.093% of the company’s shares, worth $505.99K. The average tenure of the management team and the board of directors is 4.9 years and 2.6 years respectively.
Key information
Tim Knotnerus
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 7.3yrs |
| CEO ownership | 0.09% |
| Management average tenure | 4.9yrs |
| Board average tenure | 2.6yrs |
Recent management updates
Recent updates
CEO
Tim Knotnerus (42 yo)
Dr. Tim Knotnerus, Ph D., MSc serves as Chief Executive Officer at AgomAb Therapeutics N.V. since February 2019 and its Executive Director since March 2021. He was Vice President of Corporate Development a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 7.3yrs | no data | 0.093% $ 506.0k | |
| Founder | no data | no data | no data | |
| Chief Financial Officer | 1.5yrs | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| General Counsel | 4.8yrs | no data | no data | |
| Chief Medical Officer | 5.3yrs | no data | no data | |
| Chief Business Officer | 5yrs | no data | no data | |
| Chief Development Officer | 4.3yrs | no data | no data |
Experienced Management: AGMB's management team is considered experienced (4.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 5.2yrs | no data | 0.093% $ 506.0k | |
| Founder | 2.5yrs | no data | no data | |
| Non-Executive Independent Chairman | 1.8yrs | no data | no data | |
| Senior Advisor & Member of Scientific Advisory Board | 2.5yrs | no data | no data | |
| Non-Executive Independent Director | 1.5yrs | no data | no data | |
| Board Observer | 2.6yrs | no data | no data | |
| Non-Executive Independent Director | 7.1yrs | no data | no data | |
| Board Observer | 2.6yrs | no data | no data | |
| Non-Executive Independent Director | 2.6yrs | no data | no data | |
| Non-Executive Independent Director | 2.6yrs | no data | no data |
Experienced Board: AGMB's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/03 22:08 |
| End of Day Share Price | 2026/05/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AgomAb Therapeutics NV is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anupam Rama | J.P. Morgan |
| Thomas Smith | Leerink Partners LLC |
| Judah Frommer | Morgan Stanley |